Slide 1: Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Phase 2 Study in Japanese Patients (RAMP201J)
Shogo Shigeta, MD, PhD Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Miyagi, Japan October 2, 2026 Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: A Phase 2 Study in Japanese Patients (RAMP201J) Shogo Shigeta, Muneaki Shimada, Takafumi Kurod
Slide 2: Disclosure
Disclosure X No, nothing to disclose Yes, please specify:
Slide 3: Phase 2 RAMP 201J: Study Design and Patient Baseline Characteristics
Phase 2 RAMP 201J: Study Design and Patient Baseline Characteristics Study Design Patient Baseline Characteristics and Disposition Objective: To evaluate the efficacy, pharmacokinetics, and safety of All patients Characteristic avutometinib + defactinib in Japanese patients with recurrent LGSOC (N=1
Slide 4: ORR and Best Percent Change in Target Lesions and Response (by Investigator Assessment)
ORR and Best Percent Change in Target Lesions and Response (by Investigator Assessment) 20 KRAS mt KRAS wt All patients Response rates, n (%) 8 (n=7) (n=9) (N=16) * * * * * * * * * * * SD SD SD SD SD SD SD SD PR PR PR PR PR PR PR 0 Best Percent Change in Target Lesion Confirmed ORR 5 (71) 2 (22) 7 (
Slide 5: Disease Control in Avutometinib + Defactinib in Patients With KRAS mt and KRAS wt LGSOC
Disease Control in Avutometinib + Defactinib in Patients With KRAS mt and KRAS wt LGSOC KRAS mt KRAS wt (n=7) (n=9) 80 80 60 60 Percent Change in Target Lesion Percent Change in Target Lesion 40 40 Sum of Diameters, % Sum of Diameters, % 20 20 0 0 * * * -20 -20 * -40 * -40 -60 * * -60 * * -80 * * -8
Slide 6: Safety Profile and Conclusions
Safety Profile and Conclusions Safety Profile RAMP 201J Summary All patients TRAEs,a n (%) (N=16) • Avutometinib + defactinib demonstrated promising preliminary efficacy in Preferred term All grades Grade 3b Japanese patients with recurrent LGSOC Any TRAE 16 (100) 9 (56) TRAEs (≥25% of patients) O
Slide 7: Acknowledgments
Acknowledgments We thank the patients and their families for their participation and the trial teams at participating centers for their support of this study. This study is sponsored by Verastem Oncology. For more information, please use this QR code to access an oral presentation presented at JSGO